All In Biotech

BLA 125104 · Biogen Idec

Tysabri

Natalizumab · Single-Use · Integrin Receptor Antagonist

NovelAccelerated approvalPriority review

Last checked: Nov 20, 2026Latest source record: Mar 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Nov 23, 2004

Approved uses

6

Original approval plus efficacy supplements

Registered trials

75

17 Phase 3, 6 recruiting

FAERS reports

181,255

56,644 serious, 5,131 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI [ see Warnings and Precautions ( 5.1 ) ]. Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated,...

What it is approved for

From the label in effect Oct 9, 2026.

TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) 1.1 Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [ see Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. 1.2 Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and...

Mechanism: Natalizumab binds to the α4-subunit of α4β1 and α4β7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α4-mediated adhesion of leukocytes to their counter-receptor(s). The receptors for the α4 family of integrins include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) present on vascular endothelial cells of the gastrointestinal tract. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TYSABRI · NATALIZUMAB 300MG · VIAL, SINGLE-USE · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Natalizumab" as an intervention, any sponsor and status, largest first.

All 75 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue19,632
  • multiple sclerosis relapse16,953
  • headache10,010
  • multiple sclerosis9,821
  • gait disturbance9,507
  • fall8,050
  • asthenia8,012
  • memory impairment7,972
  • malaise7,449
  • drug ineffective6,917
  • urinary tract infection6,323
  • pain5,988

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051,355
200648
2007559
20081,549
20092,555
201020,069
201125,662
201222,980
201329,497
201412,502
20157,069
20168,948
20178,570
20188,295
20196,205
20205,145
20213,964
20224,362
20233,971
20243,274
20252,831
20261,843

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tysabri (Natalizumab)

2024 spending

$37.2M

Beneficiaries

566

4,470 claims

Per beneficiary

$65,659

$565.71 per unit

View as table
YearSpending
2020$41,553,342
2021$43,445,960
2022$45,770,526
2023$40,471,107
2024$37,162,951

Part B: Tysabri (Natalizumab) · HCPCS J2323

2024 spending

$159M

Beneficiaries

2,778

22,673 claims

Per beneficiary

$57,169

2024 ASP limit $24.23 per unit

View as table
YearSpending
2020$217,864,711
2021$208,017,215
2022$204,974,045
2023$184,186,605
2024$158,815,402

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 279 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.